Regulation of Cannabinoid CB1 Receptors in the Central Nervous System by Chronic Cannabinoids

Critical Reviews in Neurobiology

Volumn 15, Issue 2, 2003, Pages 91-119

  Sim Selley, Laura J ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Basal ganglia; Cannabinoid receptor; Cerebellum; CP55,940; Delta 9 tetrahydrocannabinol; Desensitization; Downregulation; Hippocampus; Striatum; Tolerance; WIN55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABIS; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEXANABINOL; DRONABINOL; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; PSYCHOTROPIC AGENT; RIMONABANT; TETRAHYDROCANNABINOL;

ANIMAL CELL; ANIMAL TISSUE; ANTINOCICEPTION; BASAL GANGLION; BRAIN CORTEX; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG TOLERANCE; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LOCOMOTION; MEMORY DISORDER; MOUSE; NONHUMAN; PSYCHOBIOLOGY; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOWN-REGULATION; DRUG TOLERANCE; HUMANS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, G-PROTEIN-COUPLED;

EID: 0742271034     PISSN: 08920915     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevNeurobiol.v15.i2.10     Document Type: Review

References (149)

1. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38:151-178.
2. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38:1-20.
3. Jones RT, Benowitz NL, Herning RI. Clinical relevance of cannabis tolerance and dependence. J Clin Pharm Pharmacol 1981; 21:143S-152S.
4. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86:1646-1647.
5. Howlett AC, Fleming RM. Cannabinoid inhibition of adenylate cyclase: pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 1984; 26:532-538.
6. Devane WA, Dysarz FAI, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34:605-613.
7. Matsuda LA, Lolait SJ, Brownstein MJ, Young AL, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561-564.
8. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215:89-97.
9. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258:1946-1949.
10. Glass M, Dragunow M, Faull RLM. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77(2):299-318.
11. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11(2):563-583.
12. Jansen EM, Haycock DA, Ward SJ, Seybold VS. Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles. Brain Res 1992; 575:93-102.
13. Carlini EA. Tolerance to chronic administration of cannabis sativa (marihuana) in rats. Pharmacology 1968; 1:135-142.
14. McMillan DE, Dewey WL, Harris LS. Characteristics of tetrahydrocannabinol tolerance. Ann NY Acad Sci 1971; 191:83-99.
15. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 1995; 280:R13-R15.
16. Aceto MD, Scates SM, Lowe JA, Martin BR. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 1995; 282:R1-R2.
17. Maldonado R, Rodriguez de Fonseca F. Cannabinoid addiction: behavioral models and neural correlates. J Neurosci 2002; 22:3326-3331.
18. Selley DE, Lichtman AH, Martin BR. Integration of molecular and behavioral approaches to evaluate cannabinoid dependence. In: Maldonado R, editor. Molecular Biology of Drug Addiction. Totowa, NJ: Humana Press, 2002.
19. Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001; 106:1-4.
20. Di Marzo V, Breivogel CS, Tao Q, et al. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 2000; 75(6):2434-44.
21. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60(1):155-163.
22. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61-65.
23. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54:161-202.
24. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350:240-244.
25. Bouaboula M, Perrachon S, Milligan L, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. J Biol Chem 1997; 272(35):22330-22339.
26. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 1997; 334:R1-R2.
27. Sim-Selley LJ, Brunk LK, Selley DE. Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol 2001; 414(2-3):135-143.
28. Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol 1998; 359:1-18.
29. Hanus L, Abu-Lafi S, Fride E, et al. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001; 98:3662-3665.
30. 35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 1998; 273:16865-16873.
31. 9-tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. Eur J Pharmacol 1997; 323:R3-R4.
32. 35S]GTPγS autoradiography in rat brain. J Neurosci 1996; 16:8057-8066.
33. 35S]thio]-triphosphate binding. Proc Natl Acad Sci USA 1995; 92:7242-7246.
34. Breivogel CS, Sim LJ, Childers SR. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther 1997; 282(3):1632-1642.
35. Selley DE, Rorrer WK, Breivogel CS, et al. Agonist efficacy and receptor efficiency in heterozygous CB1 knockout mice: relationship of reduced CB1 receptor density to G-protien activation. J Neurochem 2001; 77:1-11.
36. Sim-Selley LJ, Vogt LJ, Vogt BA, Childers SR. Cellular localization of cannabinoid receptors and activated G-proteins in rat anterior cingulate cortex. Life Sci 2002; 71:2217-2226.
37. i in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 1986; 29:307-313.
38. s linkage to the CB1 receptor. J Neurosci 1997; 17(14):5327-5333.
39. Rhee MH, Bayewitch M, Avidor-Reiss T, Levy R, Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J Neurochem 1998; 71(4):1525-34.
40. Mons N, Cooper DMF. Adenylate cyclases: critical foci in neuronal signaling. Trends Neurosci 1995; 18:536-542.
41. Childers SR, Deadwyler SA. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem Pharmacol 1996; 52:819-827.
42. Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995; 15:6552-6561.
43. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992; 89:3825-3829.
44. Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997; 78:43-50.
45. + in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun 1997; 229:58-64.
46. Bouaboula M, Poinot-Chazel C, Bourrié B, et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 1995; 312:637-641.
47. 9-THC in rats. Physiol Genom 2000; 3:175-185.
48. Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991; 547:267-274.
49. Herkenham M, Groen BG, Lynn AB, De Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Res 1991; 552(2):301-10.
50. Mailleux P, Vanderhaeghen J-J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992; 48(3):655-668.
51. Matsuda LA, Bonner TI, Lolait SJ. Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 1993; 327:535-550.
52. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83:393-411.
53. Egertova M, Elphick MR. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB1. J Comp Neurol 2000; 422:159-171.
54. Romero J, Hillard CJ, Calero M, Rabano A. Fatty acid amide hydrolyase localization in the human central nervous system: an immunohistochemical study. Mol Brain Res 2002; 100:85-93.
55. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001; 22:565-572.
56. A-receptor synapses in the mammalian CNS. Trends Neurosci 1995; 18:333-340.
57. Kreitzer AC, Regehr WC. Retrograde signaling by endocannabinoids. Curr Opin Neurobiol 2002; 12:324-330.
58. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science 2002; 296:678-330.
59. Katona I, Sperlagh B, Sik A, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 1999; 19:4544-4558.
60. Tsou K, Mackie K, Sanudo-Pena MC, Walker JM. Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. Neuroscience 1999; 93:969-975.
61. Hampson RE, Zhuang SY, Weiner JL, Deadwyler SA. Functional significance of cannabinoid-mediated, depolarization induced suppression of inhibition (DSI) in the hippocampus. J Neurophysiol 2003; 90:55-64.
62. Martin BR, Lichtman AH. Cannabinoid transmission and pain perception. Neurobiol Dis 1998; 5:447-461.
63. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63:569-611.
64. Panikashvili D, Simeonidou C, Ben-Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413:527-531.
65. Wallace MJ, Martin BR, DeLorenzo RJ. Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur J Pharmacol 2002; 452:295-301.
66. Brotchie JM. CB1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 2003; 3:54-61.
67. Glass M. The role of cannabinoids in neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25:743-765.
68. Pertwee RG. Cannabinoids and multiple sclerosis. Pharmacol Ther 2002; 95:165-174.
69. Richfield EK, Herkenham M. Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol 1994; 36(4):577-584.
70. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000; 97(3):505-519.
71. Compton DR, Rice KC, DeCosta BR, et al. Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993; 265:218-226.
72. Patel S, Hillard CJ. Cannabinoid CB1 receptor agonists produce cerebellar dysfunction in mice. J Pharmacol Exp Ther 2001; 297:629-637.
73. DeSanty KP, Dar MS. Cannabinoid-induced motor incoordination through the cerebellar CB1 receptor in mice. Pharmacol Biochem Behavr 2001; 69:251-259.
74. Sullivan JM. Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids. Learning Mem 2000; 7:132-139.
75. Hampson RE, Deadwyler SA. Cannabinoids, hippocampal function and memory. Life Sci 1999; 65:715-723.
76. Davies SN, Pertwee RG, Riedel G. Functions of cannabinoid receptors in the hippocampus. Neuropharmacology 2002; 42:993-1007.
77. Lichtman AH, Dimen KR, Martin BR. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 1995; 119:282-290.
78. Lichtman AH, Martin BR. Delta 9-tetrahyrdocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 1996; 126:125-131.
79. Compton DR, Aceto MD, Lowe J, Martin BR. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996; 277:586-594.
80. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999; 96:5780-5785.
81. Ledent C, Valverde O, Cossu G, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283:401-404.
82. Freedland CS, Whitlow CT, Miller MD, Porrino LJ. Dose-dependent effects of delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat. Synapse 2002; 45:134-142.
83. Whitlow CT, Freedland CS, Porrino LJ. Metabolic mapping of the time-dependent effects of delta9-tetrahydrocannabinol administration in the rat. Psychopharmacology 2002; 161:129-136.
84. Whitlow CT, Freedland CS, Porrino LJ. Functional consequences of the repeated administration of delta9-tetrahydrocannabinol in the rat. Drug Alcohol Depend 2003; in press.
85. Oviedo A, Glowa J, Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res 1993; 616:293-302.
86. 9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 1993; 47:33-40.
87. 9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Mol Brain Res 1997; 46:100-108.
88. 35S]GTPgammaS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide. Neurochem Int 1999; 34:473-482.
89. Rubino T, Vigano D, Massi P, et al. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 2000; 39(7):1331-1336.
90. 9-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther 2002; 303:36-44.
91. 9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptor-activated G-proteins in brain. J Neurochem 1999; 73:2447-2459.
92. 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav 1993; 46:575-579.
93. 9-tetrahydrocannabinol. Synapse 1998; 30:298-308.
94. Rubino T, Vigano D, Massi P, Parolaro D. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J Neurochem 2000; 75(5):2080-2086.
95. Fan F, Tao Q, Abood ME, Martin BR. Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Res 1996; 706:13-20.
96. Breivogel CS, Scates SM, Beletskaya IO, Lowery OB, Aceto MD, Martin BR. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol 2003; 459:139-150.
97. Rubino T, Massi P, Patrini G, Venier I, Giagnoni G, Parolaro D. Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: an in situ hybridization study. NeuroReport 1994; 5:2493-2496.
98. Rubino T, Patrini G, Massi P, et al. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 1998; 285:813-819.
99. 9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu opioid and CB1 receptors in the caudate-putamen. Brain Res Mol Brain Res 1999; 67:148-157.
100. 9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Mol Brain Res 1998; 62:141-149.
101. Rinaldi-Carmona M, Le Duigou A, Oustric D, et al. Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. J Pharmacol Exp Ther 1998; 287(3):1038-47.
102. Hsieh C, Brown S, Derleth C, Mackie K. Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 1999; 73(2):493-501.
103. Coutts AA, Anavi-Goffer S, Ross RA, et al. Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci 2001; 21:2425-2433.
104. Pitcher JA, Freedman NJ, Lefkowitz RJ. G Protein-coupled receptor kinases. Ann Rev Biochem 1998; 67:653-692.
105. Lefkowitz RJ. G-protein-coupled receptors III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J Biol Chem 1998; 273:18677-18680.
106. Kouznetsova M, Kelley B, Shen M, Thayer SA. Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture. Mol Pharmacol 2002; 61:477-485.
107. Jin W, Brown S, Roche JP, et al. Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization. J Neurosci 1999; 19(10):3773-3780.
108. 35S]thio)triphosphate binding in rat brain membranes. Life Sci 1996; 59:659-668.
109. Breivogel CS, Childers SR. Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacol Exp Ther 2000; 295(1):328-336.
110. Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J Pharmacol Exp Ther 1992; 260(1):201-209.
111. 9-tetrahydrocannabinol. J Pharmacol Exp Ther 1992; 263:1118-1126.
112. Rubino T, Patrini G, Parenti M, Massi P, Parolaro D. Chronic treatment with a synthetic cannabinoid CP-55,940 alters G-protein expression in the rat central nervous system. Mol Brain Res 1997; 44:191-197.
113. Dill JA, Howlett AC. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J Pharmacol Exp Ther 1988; 244:1157-1163.
114. Rhee MH, Nevo I, Avidor-Reiss T, Levy R, Vogel Z. Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB(1) cannabinoid receptor. Mol Pharmacol 2000; 57(4):746-52.
115. Hutcheson DM, Tzavara ET, Smadjs C, et al. Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with Δ9-tetrahydrocannabinol. Br J Pharmacol 1998; 125:1567-1577.
116. Tzavara ET, Valjent E, Firmo C, et al. Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum. Eur J Neurosci 2000; 12:1038-1046.
117. Lee MC, Smith FL, Stevens DL, Welch SP. The role of several kinases in mice tolerant to delta9-tetrahydrocannabinol. J Pharmacol Exp Ther 2003; 305:593-599.
118. Romero J, Garciá L, Fernández-Ruiz JJ, Cebeira M, Ramos JA. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to Δ9-tetrahydrocannabinol. Pharmacol Biochem Behav 1995; 51(4):731-737.
119. 35S] thiotriphosphate) binding without receptor downregualtion in brain regions of anandamide-tolerant rats. J Neurochem 2000; 75:2478-2484.
120. Welch SP, Huffman JW, Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 1998; 286:1301-1308.
121. 9-tetrahyrocannabinol-tolerant rats. J Neurochem 2000; 74:1627-1635.
122. Prather PL, Martin NA, Breivogel CS, Childers SR. Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol Pharmacol 2000; 57(5):1000-1010.
123. Straiker AJ, Borden CR, Sullivan JM. G-protein alpha subunit isoforms couple differentially to receptors that mediate presynaptic inhibition at rat hippocampal synapses. J Neurosci 2002; 22:2460-2468.
124. Betty M, Harnish SW, Rhodes KJ, Cockett MI. Distribution of heterotrimeric G-protein b and g subunits in the rat brain. Neuroscience 1998; 85:475-486.
125. Watson JB, Coulter PM, 2nd, Margulies JE, et al. G-protein gamma 7 subunit is selectively expressed in medium-sized neurons and dendrites of the rat neostriatum. J Neurosci Res 1994; 39(1):108-16.
126. Gold SJ, Ni YG, Dohlman HG, Nestler EJ. Regulators of G-protein signaling (RGS) proteins: region-specific expression of nine subtypes in rat brain. J Neurosci 1997; 17:8024-8037.
127. Thomas EA, Danielson PE, Sutcliffe JG. RGS9: a regulator of G-protein signalling with specific expression in rat and mouse striatum. J Neurosci Res 1998; 52(1):118-24.
128. Rahman Z, Schwarz J, Gold SJ, et al. RGS9 modulates dopamine signaling in the basal ganglia. Neuron 2003; in press.
129. Wager-Miller J, Westenbrook R, Mackie K. Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example. Chem Phys Lipids 2002; 121:83-89.
130. Fitton AG, Pertwee RG. Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of delta 9-tetrahydrocannabinol. Br J Pharmacol 1982; 75:409-414.
131. Rawls SM, Cabassa J, Geller EB, Adler MW. CB1 receptors in the preoptic anterior hypothalamus regualte WIN 55212-2 [2,3-dihydro-5-methyl-3-[((morpholinyl)methyl)pyrrolo[1,2,3-de]-1, 4-benzoxazinyl]-(1-napthalenyl)methanone mesylate-induced hypothermia. J Pharmacol Exp Ther 2002; 301:963-968.
132. Lichtman AH, Martin BR. Spinal and supraspinal components of cannabinoid-induced antinociception. J Pharmacol Exp Ther 1991; 258:517-523.
133. Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 1996; 276(2):585-593.
134. Martin WJ, Tsou K, Walker JM. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett 1998; 242:33-36.
135. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Ann Rev Neurosci 1991; 14:219-245.
136. Vaughan CW, McGregor IS, Christie MJ. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol 1999; 127: 935-940.
137. Vaughn CW, Connor M, Bagley EE, Christie MJ. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol Pharmacol 2000; 57:288-295.
138. Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. Nature 1998; 395:381-383.
139. Katona I, Sperlagh B, Magloczky Z, et al. GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 2000; 100:797-804.
140. Varvel SA, Lichtman AH. Evaluation of CB1 recpetor knockout mice in the Morris water maze. J Pharmacol Exp Ther 2002; 301:915-924.
141. Deadwyler SA, Heyser CJ, Hampson RE. Complete adaptation to the memory disruptive effects of delta9-THC following 35 days of exposure. Neurosci Res Commun 1995; 17:9-18.
142. Sanudo-Pena MC, Tsou K, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999; 65(6-7):703-13.
143. Romero J, Lastres-Becker I, deMiguel R, Berrendero F, Ramos J, Fernandez-Ruiz J. The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological and therapeutic aspects. Pharmacol Ther 2002; 95:137-152.
144. Hohmann AG, Herkenham M. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 2000; 37(1):71-80.
145. Meschler JP, Howlett AC. Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 2001; 40:918-926.
146. Bidaut-Russell M, Howlett AC. Cannabinoid receptor-regulated cyclic AMP accumulation in the rat striatum. J Neurochem 1991; 57(5):1769-73.
147. Sanudo-Pena MC, Patrick SL, Patrick RL, Walker JM. Effects of intranigral cannabinoids on rotational behavior in rats: interactions with the dopaminergic system. Neurosci Lett 1996; 206:21-24.
148. Bass CE, Martin BR. Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice. Drug Alcohol Depend 2000; 60(2):113-119.
149. Sim-Selley LJ, Rorrer WK, Dalton GD, Martin BR, Selley DE. Time course for normalization of CB1 receptor levels and G-protein activation following cessation of chronic cannabinoid treatment. In: 2002 Symposium on the Cannabinoids. Burlington, Vermont: International Cannabinoid Research Society, 2002.